Sanofi - ADR (SNY): Price and Financial Metrics


Sanofi - ADR (SNY)

Today's Latest Price: $51.37 USD

0.42 (-0.81%)

Updated Aug 13 5:46pm

Add SNY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SNY Stock Summary

  • SNY has a market capitalization of $129,871,362,335 -- more than approximately 98.57% of US stocks.
  • With a year-over-year growth in debt of 54.84%, Sanofi's debt growth rate surpasses 81.58% of about US stocks.
  • The volatility of Sanofi's share price is greater than that of only 1.34% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to SNY, based on their financial statements, market capitalization, and price volatility, are PFE, DSGX, TEL, NVS, and EW.
  • SNY's SEC filings can be seen here. And to visit Sanofi's official web site, go to www.sanofi.com.
SNY Daily Price Range
SNY 52-Week Price Range

SNY Stock Price Chart Technical Analysis Charts


SNY Price/Volume Stats

Current price $51.37 52-week high $55.00
Prev. close $51.79 52-week low $37.62
Day low $51.18 Volume 623,741
Day high $51.51 Avg. volume 1,965,751
50-day MA $51.66 Dividend yield 2.26%
200-day MA $48.64 Market Cap 128.64B

Sanofi - ADR (SNY) Company Bio


Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. The company was founded in 1973 and is based in Paris, France.

SNY Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$51.37$66.51 31%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Sanofi. To summarize, we found that Sanofi ranked in the 53th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 31.5%. The most interesting components of our discounted cash flow analysis for Sanofi ended up being:

  • The compound growth rate in the free cash flow of Sanofi over the past 4.99 years is 0.02%; that's higher than only 22.35% of free cash flow generating stocks in the Healthcare sector.
  • Sanofi's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 9.13% of tickers in our DCF set.
  • SNY's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 9.13% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%28%
1%30%
2%31%
3%32%
4%33%
5%35%

MGLN, HAE, UNH, LH, and ACIU can be thought of as valuation peers to SNY, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.





SNY Latest News Stream


Event/Time News Detail
Loading, please wait...

SNY Latest Social Stream


Loading social stream, please wait...

View Full SNY Social Stream

Latest SNY News From Around the Web

Below are the latest news stories about Sanofi that investors may wish to consider to help them evaluate SNY as an investment opportunity.

Sanofi, GSK face U.S. investigation over potential Zantac carcinogen link

The U.S. Department of Justice has opened an investigation into whether drugmakers including Sanofi SA failed to disclose to the federal government information about the potential presence of a probable carcinogen in the heartburn drug Zantac.

Reuters | July 30, 2020

P/E Ratio Insights for Sanofi

In the current market session, Sanofi Inc. (NASDAQ: SNY) is trading at $52.01, after a 1.57% decrease. However, over the past …

Benzinga | July 30, 2020

Sanofi (SNY) Q2 2020 Earnings Call Transcript

SNY earnings call for the period ending June 30, 2020.

Yahoo | July 30, 2020

Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial

Nirsevimab reduced respiratory syncytial virus infections requiring medical care in healthy premature infants in Phase 2b trial  * Nirsevimab reduced respiratory syncytial virus (RSV) lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent1 * Results published in New England Journal of Medicine * The investigative immunization demonstrated sustained protection across a typical five-month RSV season with a single dose1 * Sanofi will host a nirsevimab R&D investor event today at 5 p.m. CET/11 a.m. ET PARIS – July 30, 2020 – Detailed results from the positive Phase 2b trial for nirsevimab showed a significant reduction in medically attended lower respiratory tract infections (LRTI), mainly bronchiolitis and pneumonia, and hospitalizations caused by ...

Yahoo | July 30, 2020

Sanofi EPS beats by €0.06, misses on revenue

Sanofi (SNY): Q2 Non-GAAP EPS of €1.28 beats by €0.06; GAAP EPS of €6.07.Revenue of €8.21B (-4.9% Y/Y) misses by €50M.Dupixent sales grew 70% Y/Y to €858M.Press Release...

Seeking Alpha | July 29, 2020

Read More 'SNY' Stories Here

SNY Price Returns

1-mo -1.42%
3-mo 8.70%
6-mo 5.41%
1-year 26.06%
3-year 21.77%
5-year 16.43%
YTD 4.84%
2019 23.73%
2018 4.20%
2017 8.73%
2016 -2.52%
2015 -3.37%

SNY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full SNY Dividend History

Continue Researching SNY

Want to see what other sources are saying about Sanofi's financials and stock price? Try the links below:

Sanofi (SNY) Stock Price | Nasdaq
Sanofi (SNY) Stock Quote, History and News - Yahoo Finance
Sanofi (SNY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1097 seconds.